TP53 mutation spectrum in breast cancer is subtype specific and has distinct prognostic relevance

Clinical Cancer Research

Volumn 20, Issue 13, 2014, Pages 3569-3580

  Silwal Pandit, Laxmi ^a,b   Vollan, Hans Kristian Moen ^a,b,c   Chin, Suet Feung ^e,h   Rueda, Oscar M ^e,f   McKinney, Steven ^j,k   Osako, Tomo ^j,k   Quigley, David A ^a,b,i   Kristensen, Vessela N ^a,b,d   Aparicio, Samuel ^j,k   Børresen Dale, Anne Lise ^a,b   Caldas, Carlos ^e,f,g,h   Langerød, Anita ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b Faculty of Medicine   (Norway)

^c OSLO UNIVERSITY HOSPITAL   (Norway)

^d AKERSHUS UNIVERSITY HOSPITAL   (Norway)

^e IMPERIAL CANCER RESEARCH FUND   (United Kingdom)

^f Cambridge Experimental Cancer Medicine Centre   (United Kingdom)

^g CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^h UNIVERSITY OF CAMBRIDGE   (United Kingdom)

ⁱ UNIVERSITY OF CALIFORNIA   (United States)

^j UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^k BRITISH COLUMBIA CANCER RESEARCH CENTRE   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; PROTEIN MDM2; PROTEIN P53; TUMOR MARKER;

ADULT; ARTICLE; BASAL LIKE BREAST CANCER; BREAST CANCER; BREAST CARCINOGENESIS; CANCER MORTALITY; CANCER PROGNOSIS; CANCER SPECIFIC SURVIVAL; CONTROLLED STUDY; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; GENE MUTATION; GENETIC ASSOCIATION; GENOMIC INSTABILITY; HETEROZYGOSITY LOSS; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MDM2 GENE; MUTATIONAL ANALYSIS; PRIORITY JOURNAL; TUMOR SUPPRESSOR GENE; AGED; BREAST NEOPLASMS; CANCER GRADING; COHORT ANALYSIS; FEMALE; FOLLOW UP; GENETICS; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; METABOLISM; MIDDLE AGED; MORTALITY; MULTIMODALITY CANCER THERAPY; MUTATION; NUCLEOTIDE SEQUENCE; PATHOLOGY; PROGNOSIS; TUMOR ASSOCIATED LEUKOCYTE; TUMOR VOLUME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; COHORT STUDIES; COMBINED MODALITY THERAPY; DNA MUTATIONAL ANALYSIS; FEMALE; FOLLOW-UP STUDIES; GENOMIC INSTABILITY; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; LYMPHOCYTES, TUMOR-INFILTRATING; MIDDLE AGED; MUTATION; NEOPLASM GRADING; PROGNOSIS; TUMOR BURDEN; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53; YOUNG ADULT;

EID: 84903821816     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-13-2943     Document Type: Article

References (40)

1. Curtis C, Shah SP, Chin S-F, Turashvili G, Rueda OM, Dunning MJ, et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 2012;486: 346-52.
2. Lane DP, Crawford LV. T antigen is bound to a host protein in SV40-transformed cells. Nature 1979;278: 261-3.
3. Linzer DI, Levine AJ. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40-transformed cells and uninfected embryonal carcinoma cells. Cell 1979;17: 43-52.
4. Lane D, Levine A. p53 Research: the past thirty years and the next thirty years. Cold Spring Harb Perspect Biol 2010;2: a000893.
5. Petitjean A, Mathe E, Kato S, Ishioka C, Tavtigian SV, Hainaut P, et al. Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database. Hum Mutat 2007;28: 622-9.
6. Oren M, Rotter V. Mutant p53 gain-of-function in cancer. Cold Spring Harb Perspect Biol 2010;2: a001107.
7. Muller PAJ, Vousden KH. p53 mutations in cancer. Nat Cell Biol 2013;15: 2-8.
8. Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature 2000;406: 747-52.
9. Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001;98: 10869-74.
10. Cancer Genome Atlas Research Network. Comprehensive molecular portraits of human breast tumours. Nature 2012;490: 61-70.
11. Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel AB, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 2003;100: 8418-23.
12. Hu Z, Fan C, Oh DS, Marron JS, He X, Qaqish BF, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics 2006;7: 96.
13. Harbeck N, Sotlar K, Wuerstlein R, Doisneau-Sixou S. Molecular and protein markers for clinical decision making in breast cancer: Today and tomorrow. Cancer Treat Rev 2014;40: 434-44.
14. Dawson S-J, Rueda OM, Aparicio S, Caldas C. A new genome-driven integrated classification of breast cancer and its implications. EMBO J 2013;32: 617-28.
15. Børresen-Dale A-L. TP53 and breast cancer. Hum Mutat 2003;21: 292-300.
16. Olivier M, Langerød A, Carrieri P, Bergh J, Klaar S, Eyfjord J, et al. The clinical value of somatic TP53 gene mutations in 1,794 patients with breast cancer. Clin Cancer Res 2006;12: 1157-67.
17. Alsner J, Jensen V, Kyndi M, Offersen BV, Vu P, Børresen-Dale A-L, et al. A comparison between p53 accumulation determined by immunohistochemistry and TP53 mutations as prognostic variables in tumours from breast cancer patients. Acta Oncol 2008;47: 600-7.
18. Ozçelik H, Pinnaduwage D, Bull SB, Andrulis IL. Type of TP53 mutation and ERBB2 amplification affects survival in node-negative breast cancer. Breast Cancer Res Treat 2007;105: 255-65.
19. Langerød A, Zhao H, Borgan Ø, Nesland JM, Bukholm IRK, Ikdahl T, et al. TP53 mutation status and gene expression profiles are powerful prognostic markers of breast cancer. Breast Cancer Res 2007;9: R30.
20. Holstege H, Horlings HM, Velds A, Langerød A, Børresen-Dale A-L, van de Vijver MJ, et al. BRCA1-mutated and basal-like breast cancers have similar aCGH profiles and a high incidence of protein truncating TP53 mutations. BMC Cancer 2010;10: 654.
21. Russnes HG, Vollan HKM, Lingjaerde OC, Krasnitz A, Lundin P, Naume B, et al. Genomic architecture characterizes tumor progression paths and fate in breast cancer patients. Sci Transl Med 2010;2: 38ra47-7.
22. Bilal E, Dutkowski J, Guinney J, Jang IS, Logsdon BA, Pandey G, et al. Improving Breast Cancer Survival Analysis through Competition-Based Multidimensional Modeling. PLoS Comput Biol 2013;9: e1003047.
23. Van Loo P, Nordgard SH, Lingjaerde OC, Russnes HG, Rye IH, Sun W, et al. Allele-specific copy number analysis of tumors. Proc Natl Acad Sci U S A 2010;107: 16910-5.
24. R Core Team (2014). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna, Austria. http://www.R-project.org/.
25. Frank E Harrell Jr (2014). rms: Regression Modeling Strategies. R package version 4.2-0. http://CRAN.R-project.org/package=rms.
26. Harrell FE. Regression modeling strategies. Springer Verlag; 2001.
27. Burns MB, Lackey L, Carpenter MA, Rathore A, Land AM, Leonard B, et al. APOBEC3B is an enzymatic source of mutation in breast cancer. Nature 2013;494: 366-70.
28. Hanel W, Moll UM. Links between mutant p53 and genomic instability. J Cell Biochem 2012;113: 433-9.
29. Hicks JB, Krasnitz A, Lakshmi B, Navin NE, Riggs M, Leibu E, et al. Novel patterns of genome rearrangement and their association with survival in breast cancer. Genome Res 2006;16: 1465-79.
30. Powell B, Soong R, Iacopetta B, Seshadri R, Smith DR. Prognostic significance of mutations to different structural and functional regions of the p53 gene in breast cancer. Clin Cancer Res 2000;6: 443-51.
31. Végran F, Rebucci M, Chevrier S, Cadouot M, Boidot R, Lizard-Nacol S. Only missense mutations affecting the DNA binding domain of p53 influence outcomes in patients with breast carcinoma. PLoS ONE 2013;8: e55103.
32. Fernández-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K-S, Quinaux E, Buyse M, et al. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline-or anthracycline/taxane-based adjuvant therapy: results from the BIG 02-98 phase III trial. Breast Cancer Res 2012;14: R70.
33. Rossner P, Gammon MD, Zhang Y-J, Terry MB, Hibshoosh H, Memeo L, et al. Mutations in p53, p53 protein overexpression and breast cancer survival. J Cell Mol Med 2009;13: 3847-57.
34. Børresen-Dale A-L, Andersen TI, Eyfjörd JE, Cornelis RS, Thorlacius S, Borg A, et al. TP53 mutations and breast cancer prognosis: particularly poor survival rates for cases with mutations in the zinc-binding domains. Genes Chromosomes Cancer 1995;14: 71-5.
35. Overgaard J, Yilmaz M, Guldberg P, Hansen LL, Alsner J. TP53 mutation is an independent prognostic marker for poor outcome in both node-negative and node-positive breast cancer. Acta Oncol 2000;39: 327-33.
36. Freed-Pastor WA, Mizuno H, Zhao X, Langerød A, Moon S-H, Rodriguez-Barrueco R, et al. Mutant p53 disrupts mammary tissue architecture via the mevalonate pathway. Cell 2012;148: 244-58.
37. Teschendorff AE, Miremadi A, Pinder SE, Ellis IO, Caldas C. An immune response gene expression module identifies a good prognosis subtype in estrogen receptor negative breast cancer. Genome Biol 2007;8: R157.
38. Schmidt M, Böhm D, Törne von C, Steiner E, Puhl A, Pilch H, et al. The humoral immune systemhas a key prognostic impact in node-negative breast cancer. Cancer Res 2008;68: 5405-13.
39. Rody A, Holtrich U, Pusztai L, Liedtke C, Gaetje R, Ruckhaeberle E, et al. T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res 2009;11: R15.
40. 1000 Genomes Project Consortium Abecasis GR, Altshuler D, Auton A, Brooks LD, Durbin RM, et al. A map of human genome variation from population-scale sequencing. Nature 2010;467: 1061-73.